logo
logo

Nuevocor Closes Us$24M Series A Financing To Advance Novel Gene Therapies For Cardiomyopathies

Jun 18, 2021•about 4 years ago

Amount Raised

$24 Million

Round Type

series a

Description

Nuevocor, a preclinical-stage biotech company specializing in gene therapy for cardiomyopathies, has announced the completion of an oversubscribed $24 million Series A financing round. The round was co-led by EVX Ventures and Boehringer Ingelheim Venture Fund (BIVF), with EDBI, Xora Innovation, SEEDS Capital and other investors joining the syndicate.

Company Information

Company

Nuevocor

About

Nuevocor is the latest company to emerge from our venture creation ecosystem. Headquartered in Singapore, Nuevocor is a privately held preclinical-stage biopharmaceutical company focused on developing AAV gene therapy for the treatment of genetically defined cardiac diseases with high unmet need. Together with AAV gene therapy and cardiac disease modelling expertise of scientific co-founders Mark Kay from Stanford University and Jianming Jiang from the National University of Singapore respectively, Nuevocor is well-positioned to treat LMNA and other genetic cardiomyopathies, amongst other cardiac diseases.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech